G
Greg Conn
Researcher at Merck & Co.
Publications - 6
Citations - 961
Greg Conn is an academic researcher from Merck & Co.. The author has contributed to research in topics: Vascular endothelial growth factor A & Growth factor. The author has an hindex of 3, co-authored 3 publications receiving 953 citations.
Papers
More filters
Journal ArticleDOI
Amino acid and cDNA sequences of a vascular endothelial cell mitogen that is homologous to platelet-derived growth factor.
Greg Conn,Marvin L. Bayne,Denis D. Soderman,P W Kwok,Kathleen A. Sullivan,T M Palisi,D A Hope,Kenneth A. Thomas +7 more
TL;DR: Glioma-derived vascular endothelial cell growth factor (GD-VEGF) is a 46-kDa dimeric glycoprotein mitogen with apparently greater specificity for vascular endothelium cells than the well-characterized fibroblast growth factors.
Journal ArticleDOI
Purification and Characterization of a Naturally Occurring Vascular Endothelial Growth Factor · Placenta Growth Factor Heterodimer
Jerry DiSalvo,Marvin L. Bayne,Greg Conn,Perry W. Kwok,Prashant Trivedi,Denis D. Soderman,Thomas M. Palisi,Kathleen A. Sullivan,Kenneth A. Thomas +8 more
TL;DR: The existence of not only homodimer but also heterodimers clearly extends the similarity between the VEGF/PlGF and the homologous platelet-derived growth factor systems.
Journal ArticleDOI
Purification of a glycoprotein vascular endothelial cell mitogen from a rat glioma-derived cell line.
Greg Conn,Denis D. Soderman,Marie-Therese Schaeffer,Michael Wile,Victor B. Hatcher,Kenneth A. Thomas +5 more
TL;DR: A growth factor that is mitogenic for vascular endothelial cells, with an ED50 of approximately 1 ng/ml, has been purified 170,000-fold to apparent homogeneity from tissue culture medium conditioned by a rat glioma-derived cell line, suggesting that this secretable growth factor could be readily available in the extracellular space under normal physiological conditions in vivo.
Journal ArticleDOI
Preliminary Safety of PDS0101 (Versamune +HPVmix) and Pembrolizumab Combination Therapy in Subjects with Recurrent/Metastatic Human Papillomavirus-16 Positive Oropharyngeal Squamous Cell Carcinoma (OPSCC)
L E P Wood,Ashish V. Chintakuntlawar,K. Price,John M. Kaczmar,Greg Conn,Frank K. Bedu-Addo,Jared Weiss +6 more
TL;DR: In this paper , the combination of checkpoint inhibitor (CPI) and pembrolizumab is shown to be safe and well tolerated without evidence of enhanced or significant toxicity.
Journal ArticleDOI
Abstract B24: Development of targeted T-cell cancer immunotherapies based on a novel enantiomeric cationic lipid that promotes antigen cross-presentation and upregulation of type I interferons
Siva K. Gandhapudi,Karuna Sundarapandiyan,Martin Ward,Afsheen Fatima,Mania Dorrani,Mary G. Banoub,Joe J. Dervan,Lauren V. Wood,Greg Conn,Jerold G. Woodward +9 more
TL;DR: Gandhapudi et al. as mentioned in this paper used the enantiomeric cationic lipid R-DOTAP nanoparticle platform (Versamune®) to promote cross presentation of multi-epitope human papilloma virus (HPV) antigens and upregulation of Type I interferons, leading to high levels of antigen-specific cytolytic polyfuctional CD8+ T-cells in vivo and complete regression of TC-1 tumors in preclinical models.